Table 1.
Quinone | Treatment conditions | Lesion Type | Method of Detection | Reference |
---|---|---|---|---|
4-OHEN | 4-OHEN + Sprague-Dawley rat mammary gland | DNA strand scission | Comet assay | Zhang et al.40 |
4-OHEN | 4-OHEN + Sprague-Dawley rat mammary gland | 8-Oxo-dG and 8-oxo-dA | SID-LC/MS/MS | Zhang et al.40 |
4-OHEN | 4-OHEN + S30 human breast cancer cells | 8-Oxo-dG | SID-LC/MS/MS and Comet assay coupled with Fpg | Wang et al.47 |
4-OHEN | 4-OHEN + Calf thymus DNA + NADPH + CuCl2 | 8-Oxo-dG and apurinic sites/apyridiminic sites | SID-LC/MS/MS and aldehyde reactive probe | Wang et al.47 |
BPQ | BPQ + NADPH + CuCl2 + poly-dG:poly-dC or phage DNA | DNA strand scission | Electrophoresis | Flowers et al.45 |
BPQ | BPQ + NADPH + CuCl2 + calf thymus DNA | Apurinic sites/apyridiminic sites | Aldehyde reactive probe | Park et al.41 |
8-Oxo-dG | EC-HPLC | |||
BAQ | BAQ+ NADPH + CuCl2 + calf thymus DNA | Apurinic sites/apyridiminic sites | Aldehyde reactive probe | Park et al.41 |
8-Oxo-dG | EC-HPLC | Seike et al.58 | ||
DMBAQ | DMBAQ + NADPH + CuCl2 + calf thymus DNA | Apurinic sites/apyridiminic sites | Aldehyde reactive probe | Park et al.41 |
8-Oxo-dG | EC-HPLC | |||
BPQ | BPQ + NADPH + CuCl2 + p53 plasmid DNA | 8-Oxo-dG | EC-HPLC | Park et al.49 |
BAQ | BAQ + NADPH + CuCl2 + p53 plasmid DNA | 8-Oxo-dG | EC-HPLC | Park et al.49 |
DMBAQ | DMBAQ + NADPH + CuCl2 + p53 plasmid DNA | 8-Oxo-dG | EC-HPLC | Park et al.49 |
BPQ | BPQ + H358 human lung epithelial cells | 8-Oxo-dG | SID-LC/MS/MS Comet assay coupled to OGG1 |
Mangal et al.82 |
BPQ | B[a]P-7,8-trans-dihydrodiol + A549 cells ± COMT inhibitor | 8-Oxo-dG | SID-LC/MS/MS Comet assay coupled to OGG1 |
Park et al.96 |
4-OHEN = 4-hydroxyequilenin; BPQ = benzo[a]pyrene-7,8-dione; BAQ = benz[a]anthracene-3,4-dione; DMBAQ = 7,12-dimethylbenz[a]anthracene-3,4-dione.